JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL

Summary

This is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial conducted in patients with relapsed or refractory pediatric B-cell acute lymphoblastic leukemia to evaluate the safety and efficacy of JY509 universal NK cell injection.

Timeline

Start

2026-01-20

Primary completion

2029-01-01

Completion

2029-04-01

Drugs

Indications